|
|
|
市場調査レポート
米国における国土安全保障（HLS）の医薬品・薬品分野に関する研究開発：プログラムと政府資金援助
U.S. Homeland Security Pharmaceuticals & Chemicals R&D -Programs and Funding Opportunities
|
Abstract
Introduction
Homeland Security (HLS) and Homeland Defense (HLD) activities, both within
government and in the private sector, combine together to create the
technological part of America' s effort to mitigate/protect against threat of
terror attacks. The structure is complex, contains a substantial area of
overlapping responsibilities, many redundancies and duplicate activities, and
has a multitude of R&D projects woven into it.
Providing a security blanket to the population in preventing as well as
minimizing the effects of terror is a complicated task that no single approach
can fully accomplish. Therefore, the government' s strategy comprises of
investing in three complementary technology directions that together will form
a comprehensive security solution:
Advanced Technologies R&D whose goal will be to develop novel means for the
purpose of detecting a terrorist threat before it is being carried out. Such
detection capability will be critical in protecting the population against
CBRNE threats. Novel detection concepts are required all across the spectrum,
as current technologies are inadequate at best.
Pharmaceuticals and Chemicals R&D which is comprised of the development of new
therapeutics and vaccines whose purpose will be to minimize the damage after
an attack takes place. In particular, novel vaccines and drugs that counter
recognized biological terror threats can minimize the damage of such attacks.
Information Technology R&D whose goal will be to develop IT-based technology
that will allow for rapid communication and analysis of HLS-related data. This
third technological thrust is crucial for the both the proper functioning of
emergency response crews after a catastrophic event takes place, as well as
for the recognition that a terror event from an unknown threat is taking
place. The need for networked information technology is critical as neither
detector technology nor the pharmaceuticals that will be developed will be
able to mitigate unknown Emerging Threats. New threats will go undetected by
the automated instruments, and can only be made known if an abnormal amount of
human casualties suddenly reported.
Some of the main questions that this report answers are:
- What is the size of the Federal government' s HLS Pharmaceuticals and
chemicals R&D funding, and which agencies are responsible for performing and
financing Research & Development?
- What are the main Research & Development institutions and organizations
related to HLS Pharmaceuticals and Chemicals R&D?
- What are the main HLS Pharmaceuticals and Chemicals R&D applications; who
sets priorities in this new environment and how?
- What are the specific Pharmaceuticals and Chemicals R&D programs (from all
Federal agencies), and what is the associated funding that has relevancy to
HLS applications?
The report is divided into two major parts:
- Part 1 - a complete description of the entire HLS Pharmaceuticals &
Chemicals R&D activity that is funded by the many participating Federal
agencies. We describe agencies, resources, programs and provide budgetary
overview for trends in R&D funding for Homeland Security and Homeland Defense
markets.
- Part 2 - describes in detail HLS Chemicals & Pharmaceuticals R&D
applications, by mission, the participating funding agencies, categories of
projects funded by each agency, current and future funding of HLS R&D programs
that we were able to find, and an outlook of future R&D Funding Opportunities
activity.
Table of Contents
1. Executive Summary
- 1.1. Introduction
- 1.2. Basic Scenario Assumptions
- 1.3. Methodology
- 1.4. Major Research Findings
- 1.4.1. U.S. HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 1.4.2. U.S. HLS Pharmaceuticals R&D Market Forecast - 2006- 2010
- 1.5. Major Research Conclusions
2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006 - 2010
- 2.1. U.S. Homeland Security R&D Structure
- 2.2. U.S. HLS Pharmaceuticals R&D - Participating Agencies & Funding -
2006- 2010
- 2.3. U.S. HLS Pharmaceuticals R&D Outlay - Overview 2006 - 2010
- 2.4. U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006-
2010
- 2.5. U.S. HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 2.6. U.S. HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006-
2010
3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 3.1. NIH (DHHS) - Homeland Security Mission
- 3.2. CDC (DHHS) - Homeland Security Mission
- 3.3. FDA (DHHS) - Homeland Security Mission
- 3.4. DHHS - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 3.4.1. DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application -
2006- 2010
- 3.5. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast -
2006- 2010
- 3.6. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 3.7. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 4.1. DOD - General Structure of R&D Budget & Fund Allocations
- 4.2. DOD - R&D Policy Making Hierarchy
- 4.3. U.S. ARMY - R&D Funding Agencies
- 4.3.1. U.S. ARMY Research Office (ARO)
- 4.3.2. U.S. ARMY Research Laboratory (ARL)
- 4.4. DOD - Defense Advanced Research Projects Agency (DARPA)
- 4.5. DOD - Chemical and Biological Defense Program (CBDP)
- 4.6. DOD - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 4.6.1. DOD - HLS Pharmaceuticals R&D Budget Forecast by Application -
2006- 2010
- 4.6.2. DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency - 2006-
2010
- 4.7. DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006-
2010
- 4.8. DOD - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 4.9. DOD - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 5.1. Outline and Resources
- 5.2. DHS - Science & Technology Division (S&T)
- 5.3. S&T Directorate - Major Groups
- 5.3.1. DHS - Office of Programs Plans & Budgets (PPB)
- 5.3.2. DHS - Homeland Security Advanced Research Projects Agency
(HSARPA)
- 5.3.3. DHS - Office of R&D
- 5.3.4. DHS - Office of Systems Engineering and Development (SED)
- 5.4. DHS - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 5.5. DHS - Pharmaceuticals R&D Budget Forecast by Application - 2006- 2010
- 5.6. DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006-
2010
- 5.6.1. Allocation to Private, Academia & Government Sectors - 2006 -
2010
- 5.7. DHS - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 5.8. DHS - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 6.1. DOE - HLS R&D Sources
- 6.2. DOE - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 6.3. DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006-
2010
- 6.4. DOE - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 6.5. DOE - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 7.1. USDA - HLS R&D Sources
- 7.2. USDA - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 7.3. USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast -
2006- 2010
- 7.4. USDA - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 7.5. USDA - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- 8.1. EPA - HLS R&D Sources
- 8.2. EPA - HLS Pharmaceuticals R&D Program Summary & Budget Forecast -
2006- 2010
- 8.2.1. EPA - HLS Pharmaceuticals R&D Budget Forecast by Application -
2006- 2010
- 8.3. EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006-
2010
- 8.4. EPA - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006-
2010
- 8.5. EPA - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors -
2006- 2010
9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 9.1. Summary & Outlook
- 9.2. Biological Therapeutics - HLS R&D Budget Forecast by Major
Departments - 2006- 2010
- 9.2.1. DHHS - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- 9.2.2. DOD - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- 9.3. Biological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast - 2006 - 2010
- 9.4. Biological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Drivers - 2006- 2010
- 9.5. Biological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Inhibitors - 2006- 2010
- 9.6. NIH & NIAID (DHHS) - Biological Therapeutics HLS Pharmaceuticals R&D
Programs
- 9.6.1. Category A Agents: Development of Biomedical Measures
- 9.7. DARPA (DOD) - Biological Therapeutics HLS Pharmaceuticals R&D
Programs
- 9.7.1. Unconventional Therapeutics
- 9.8. CBDP (DOD) - Biological Therapeutics HLS Pharmaceuticals R&D Programs
- 9.8.1. Project TB1 Medical Biological Defense (Basic Research) -
Therapeutics
- 9.8.2. Project TB2 Medical Biological Defense (Applied Research) -
Therapeutics
- 9.8.3. Project TB3 Medical Biological Defense (ATD)
10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 10.1. Summary & Outlook
- 10.2. Vaccines - HLS Pharmaceuticals R&D Budget Forecast by Major
Departments - 2006- 2010
- 10.2.1. DHHS - Vaccines HLS Pharmaceuticals R&D
- 10.2.2. DOD - Vaccines HLS Pharmaceuticals R&D
- 10.3. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Forecast -
2006- 2010
- 10.4. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Drivers -
2006- 2010
- 10.5. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors
- 2006- 2010
- 10.6. NIH & NIAID (DHHS) - Vaccines HLS Pharmaceuticals R&D Programs
- 10.6.1. Category A Agents: Development of Biomedical Measures
- 10.6.2. Category B and C Priority Pathogens and Toxins
- 10.7. ARMY (DOD) - Vaccines HLS Pharmaceuticals R&D Programs
- 10.7.1. Medical Technology - Infectious Diseases
- 10.7.2. Medical Advanced Technology - Infectious Diseases
- 10.8. CBDP (DOD) - Vaccines HLS Pharmaceuticals R&D Programs
- 10.8.1. Project TB1 Medical Biological Defense (Basic Research) -
Vaccines
- 10.8.2. Project TB2 Medical Biological Defense (Applied Research) -
Vaccines
- 10.8.3. Project TB3 Medical Biological Defense (ATD) - Vaccines
- 10.8.4. Project MB4 Medical Biological Defense (ACD&P) - Vaccines
- 10.8.5. Project MB5 Medical Biological Defense (SDD) - Vaccines
11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 11.1. Summary & Outlook
- 11.2. DOD - Chemical Therapeutics - HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- 11.3. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast - 2006 - 2010
- 11.4. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Drivers - 2006 - 2010
- 11.5. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Inhibitors - 2006 - 2010
- 11.6. CBDP (DOD) - Chemical Therapeutics - HLS Pharmaceuticals R&D
Programs
- 11.6.1. Project TC1 Medical Chemical Defense (Basic Research) -
Therapeutics
- 11.6.2. Project TC2 Medical Chemical Defense (Applied Research) -
Therapeutics
- 11.6.3. Project TC2 Medical Chemical Defense (Applied Research) -
Pretreatments
- 11.6.4. Project TC3 Medical Chemical Defense (ATD) - Therapeutics
- 11.6.5. Project TC3 Medical Chemical Defense (ATD) - Pretreatments
- 11.6.6. Project MC4 Medical Chemical Defense (ACD&P) - Therapeutics
- 11.6.7. Project MC4 Medical Chemical Defense (ACD&P)
12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 12.1. Summary & Outlook
- 12.2. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D by
Major Departments Forecast - 2006- 2010
- 12.2.1. NIH (DHHS) - Nuclear/Radiological Therapeutics - HLS
Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 12.2.2. DOD - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals
R&D Budget Forecast - 2006- 2010
- 12.2.3. DOE - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals
R&D Budget Forecast - 2006- 2010
- 12.3. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast - 2006- 2010
- 12.4. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Drivers - 2006- 2010
- 12.5. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Inhibitors - 2006- 2010
- 12.6. NIH (DHHS) - Nuclear/Radiological Therapeutics - HLS
Pharmaceuticals R&D Programs
- 12.6.1. Therapeutics for Radiation Damage
- 12.7. CBDP (DOD) - Nuclear/Radiological Therapeutics - HLS
Pharmaceuticals R&D Programs
- 12.7.1. Project TR2 Medical Radiological Defense (Applied Research)
- 12.7.2. Project TR3 Medical Radiological Defense (ATD)
- 12.7.3. Project MR4 Medical Radiological Defense
- 12.8. DOE - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Programs
- 12.8.1. Low Dose Radiation research
13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 13.1. Summary & Outlook
- 13.2. Decontamination - HLS Pharmaceuticals R&D by Major Departments
Forecast - 2006- 2010
- 13.2.1. EPA - Decontamination HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 13.2.2. DOD - Decontamination HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 13.2.3. DHS - Decontamination HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 13.2.4. DOE - Decontamination HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 13.2.5. TSWG - Decontamination HLS Pharmaceuticals R&D Budget Forecast
- 2006- 2010
- 13.3. Decontamination - HLS Pharmaceuticals R&D Funding Opportunities
Forecast - 2006- 2010
- 13.4. Decontamination - HLS Pharmaceuticals R&D Funding Opportunities
Drivers - 2006- 2010
- 13.5. Decontamination HLS Pharmaceuticals R&D Funding Opportunities
Inhibitors - 2006- 2010
- 13.6. DHS - Decontamination HLS Pharmaceuticals R&D Programs
- 13.6.1. Response and Recovery
- 13.6.2. Decontamination of Porous Surfaces after a Radiological Attack
- 13.6.3. Expedient Mitigation of a Radiological Release
- 13.7. DARPA (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
- 13.7.1. Immune Buildings
- 13.7.2. External protection
- 13.8. CBDP (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
- 13.8.1. Project CB1 - Decontamination
- 13.8.2. Project CB2 - Decontamination
- 13.8.3. Project CB3 Biological Defense (ATD) - Decontamination
- 13.8.4. Project DE4 Decontamination Systems (ACD&P)
- 13.8.5. Project DE5 Decontamination Systems (SDD)
- 13.9. ARMY (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
- 13.9.1. Environmental Quality Technology
- 13.10. DOE - Decontamination HLS Pharmaceuticals R&D Programs
- 13.10.1. Environmental Remediation Science Research
- 13.11. EPA - Decontamination HLS Pharmaceuticals R&D Programs
- 13.11.1. Water Infrastructure Decontamination
- 13.11.2. Threat and Consequence Assessment
- 13.11.3. Nonstandard Methods
- 13.11.4. Decontamination for Buildings, Large Structures, and Outdoor
Areas
- 13.11.5. Toxicity, Infectivity, and Mechanism of Action
- 13.12. TSWG - Decontamination HLS Pharmaceuticals R&D Programs
- 13.12.1. Statistical Design Tool for Sampling Contaminated Buildings
- 13.12.2. Decontamination
14.Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 14.1. Summary & Outlook
- 14.2. Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget
Forecast - 2006- 2010
- 14.2.1. DHHS - Diagnostics HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 14.2.2. DOD - Diagnostics HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- 14.3. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Forecast - 2006- 2010
- 14.4. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Drivers
- 2006- 2010
- 14.5. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Inhibitors - 2006- 2010
- 14.6. NIH & NIAID (DHHS) - Diagnostics HLS Pharmaceuticals R&D Programs
- 14.6.1. Category A Agents: Development of Diagnostic Measures
- 14.7. ARMY (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
- 14.7.1. Infectious Diseases
- 14.8. DARPA (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
- 14.8.1. Advanced Diagnostics
- 14.9. CBDP (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
- 14.9.1. Project TB1 Medical Biological Defense (Basic Research) -
Diagnostics
- 14.9.2. Project TB2 Medical Biological Defense (Applied Research) -
Diagnostics
- 14.9.3. Project TB3 Medical Biological Defense (ATD) - Diagnostics
- 14.9.4. Project MB5 Medical Biological Defense (SDD) - Diagnostics
- 14.9.5. Project TC1 Medical Chemical Defense (Basic Research) -
Diagnostics
- 14.9.6. Project TC2 Medical Chemical Defense (Applied Research) -
Diagnostics
- 14.9.7. Project TC3 Medical Chemical Defense (ATD) - Diagnostics
15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 15.1. Summary & Outlook
- 15.2. Food Protection Treatments - HLS Pharmaceuticals R&D by Major
Departments Forecast - 2006- 2010
- 15.2.1. DHHS - Food Protection Treatments HLS Pharmaceuticals R&D
Forecast - 2006- 2010
- 15.2.2. USDA - Food Protection Treatments HLS Pharmaceuticals R&D
Forecast - 2006- 2010
- 15.2.3. DHS - Food Protection Treatments HLS Pharmaceuticals R&D
Forecast - 2006- 2010
- 15.3. Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Forecast - 2006- 2010
- 15.4. Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Drivers - 2006- 2010
- 15.5. Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Inhibitors - 2006- 2010
- 15.6. DHS - Food Protection Treatments HLS Pharmaceuticals R&D Programs
- 15.7. FDA (DHHS) - Food Protection Treatments HLS Pharmaceuticals R&D
Programs
- 15.7.1. Food Defense Research
- 15.8. USDA - Food Protection Treatments HLS Pharmaceuticals R&D Programs
- 15.8.1. Livestock Protection
- 15.9. NIH (DHHS) - Food Protection Treatments HLS Pharmaceuticals R&D
Programs
- 15.9.1. Food and Water-Borne Diseases
16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- 16.1. Summary & Outlook
- 16.2. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals
R&D Budget Forecast by Major Departments- 2006- 2010
- 16.2.1. DHHS - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 16.2.2. DOD - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 16.2.3. DHS - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 16.2.4. NSF - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast - 2006- 2010
- 16.3. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals
R&D Funding Opportunities Forecast - 2006- 2010
- 16.4. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals
R&D Funding Opportunities Drivers - 2006- 2010
- 16.5. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals
R&D Funding Opportunities Inhibitors - 2006- 2010.
- 16.6. DHS - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.6.1. Threat Awareness and Characterization
- 16.6.2. Forensics
- 16.7. NIH & NIAID (DHHS) - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.7.1. Sequencing of Microorganisms
- 16.7.2. Developing Research Tools
- 16.7.3. Understanding, Assessing, and Enhancing Host Immunity
- 16.8. CDC (DHHS) - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.8.1. Reduce the Spread of Anti-Microbial Resistance
- 16.9. DARPA (DOD) - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.9.1. Biological Adaptation, Assembly, and Manufacture
- 16.9.2. Nanostructure in Biology
- 16.10. CBDP (DOD) - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.10.1. Project CB1 Biological Defense (Basic Research) - Other
- 16.10.2. Project TB1 Medical Biological Defense (Basic Research) -
Multi-Agent Medical Countermeasures
- 16.10.3. Project TB2 Medical Biological Defense (Applied Research)
Emerging Threats
- 16.10.4. Project TB3 Medical Biological Defense (ATD) - Emerging Threats
- 16.10.5. Project MB5 Medical Biological Defense (SDD) - Critical
Reagents Program (CRP)
- 16.10.6. Project TC1 Medical Chemical Defense (Basic Research) -
Emerging Threats
- 16.10.7. Project TC2 Medical Chemical Defense (Applied Research)
Emerging Threats
- 16.10.8. Project TC3 Medical Chemical Defense (ATD) - Emerging Threats
- 16.10.9. Project CB2 Chemical Defense (Applied Research) - Threat Agent
Sciences
- 16.11. NSF - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Programs
- 16.11.1. Fundamental Research to Enhance Homeland Security
17. Investing In HLS Technology
- 17.1. A Word of Caution
- 17.2. HLS Industry Experts
- 17.3. Competitive Intelligence
- 17.4. A Second Opinion
Appendix A: The Homeland Security Federal R&D Infrastructure
- A.1. SBIR (Small Business Innovations Research) R&D Funding
- A.2. STTR (Small Business Technology Transfer Program) R&D Funding
List of Figures
1. Executive Summary
- Figure 1 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application
[ $B ] - 2006- 2010
- Figure 2 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application
Share - 2004, 2006 & 2010
- Figure 3 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector [ $B ] - 2006- 2010
- Figure 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 5 - Overview of Entire Homeland Security and Homeland Defense
Infrastructure
- Figure 6 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency
[ $B ] - 2006- 2010
- Figure 7 - Federal HLS Pharmaceuticals R&D Budget Forecast by Agency Share
- 2004, 2006 & 2010
- Figure 8 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector [ $B ] - 2006- 2010
- Figure 9 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 10 - U.S. HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $B ] - 2006- 2010
- Figure 11 - U.S. HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $B ] - 2006- 2010
- Figure 12 - U.S. HLS Pharmaceuticals R&D Government Funding Opportunities
Forecast [ $B ] - 2006- 2010
3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 13 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $B ] - 2006- 2010
- Figure 14 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application
Share - 2004, 2006 & 2010
- Figure 15 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $B ] - 2006- 2010
- Figure 16 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 17 - DHHS - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 18 - DHHS - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 19 - DHHS - HLS Pharmaceuticals R&D Government Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010 Figure 20 - DOD - R&D Oversight and Funding Allocation
- Figure 21 - DOD - Historical Trends in Defense R&D [ $B ] - 2000 -
2006
- Figure 22 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $M ] - 2006- 2010
- Figure 23 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application
- 2004, 2006 & 2010
- Figure 24 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency
[ $M ] - 2006- 2010
- Figure 25 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency Share
- 2004, 2006 & 2010
- Figure 26 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Figure 27 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 28 - DOD - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 29 - DOD - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 30 - DOD - HLS Pharmaceuticals R&D Government Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 31 - DHS - Science and Technology Division (S&T) - Organizational
Chart
- Figure 32 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $B ] - 2006- 2010
- Figure 33 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application
Share - 2004, 2006 & 2010
- Figure 34 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $B ] - 2006- 2010
- Figure 35 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 36 - DHS - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 37 - DHS - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 38 - DHS - HLS Pharmaceuticals R&D Government Funding
Opportunities Forecast [ $M ] - 2006- 2010
6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 39 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast
[ $M ] - 2006- 2010
- Figure 40 - DOE - HLS Pharmaceuticals R&D Budget Forecast by Application
Share - 2004, 2006 & 2010
- Figure 41 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Figure 42 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 43 - DOE - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 44 - DOE - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 45 - DOE - HLS Pharmaceuticals R&D Government Funding
Opportunities Forecast [ $M ] - 2006- 2010
7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 46 - USDA - Food and Water Treatment R&D Budget Forecast [ $B ]
- 2006- 2010
- Figure 47 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Figure 48 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 49 - USDA - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 50 - USDA - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 51 - USDA - HLS Pharmaceuticals R&D Government Funding
Opportunities Forecast [ $M ] - 2006- 2010
8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Figure 52 - EPA - Decontamination R&D Budget Forecast [ $M ] - 2006-
2010
- Figure 53 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Figure 54 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector - 2004, 2006 & 2010
- Figure 55 - EPA - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 56 - EPA - HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 57 - EPA - HLS Pharmaceuticals R&D Government Funding
Opportunities Forecast [ $M ] - 2006- 2010
9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 58 - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast by Major Departments [ $M ] - 2006- 2010
- Figure 59 - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast by Major Departments Share - 2004, 2006 & 2010
- Figure 60 - DHHS - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast [ $M ] - 2006- 2010
- Figure 61 - DOD - Biological Therapeutics HLS Pharmaceuticals R&D Budget
Forecast [ $M ] - 2006- 2010
- Figure 62 - Biological Therapeutics HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Figure 63 - Biological Therapeutics HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector - 2004, 2006 & 2010
- Figure 64 - Biological Therapeutics HLS Pharmaceuticals R&D Private Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 65 - Biological Therapeutics HLS Pharmaceuticals R&D Academia
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 66 - Biological Therapeutics HLS Pharmaceuticals R&D Government
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 67 - Unconventional Therapeutics - Program Funding [ $M ] -
2004- 2007
- Figure 68 - Project TB1 Medical Biological Defense (Basic Research)
Therapeutics - Program Funding [ $M ] - 2004 - 2010
- Figure 69 - Project TB2 Medical Biological Defense (Applied Research)
Therapeutics - Program Funding [ $M ] - 2004- 2007
- Figure 70 - Project TB3 Medical Biological Defense (ATD) - Program
Funding [ $M ] - 2004- 2007
10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 71 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major
Departments [ $B ] - 2006- 2010
- Figure 72 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major
Departments Share - 2004, 2006 & 2010
- Figure 73 - DHHS - Vaccines HLS Pharmaceuticals R&D Budget Forecast
[ $M ] - 2006- 2010
- Figure 74 - DOD - Vaccines HLS Pharmaceuticals R&D Budget Forecast
[ $M ] - 2006- 2010
- Figure 75 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities
Forecast by Sector [ $B ] - 2006- 2010
- Figure 76 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities
Forecast Share by Sector - 2004, 2006 & 2010
- Figure 77 - Vaccines HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 78 - Vaccines HLS Pharmaceuticals R&D Academia Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 79 - Vaccines HLS Pharmaceuticals R&D Government Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 80 - Scrub Typhus Vaccine - Program Funding [ $M ] - 2004 -
4007
- Figure 81 - Vaccines against Dengue Fever, Meningitis and Hemorrhagic
Fevers - Program Funding [ $M ] - 2004- 2007
- Figure 82 - Dengue, Meningitis and Hemorrhagic Fever with Renal Syndrome
(HFRS) Vaccines - Program Funding [ $M ] - 2004- 2010
- Figure 83 - Project TB1 Medical Biological Defense (Basic Research) -
Vaccines - Program funding [ $M ] - 2004- 2007
- Figure 84 - Project TB2 Medical Biological Defense (Applied Research) -
Vaccines - Program Funding [ $M ] - 2004- 2007
- Figure 85 - Project TB3 Medical Biological Defense (Applied Research) -
Vaccines - Program Funding [ $M ] - 2004- 2007
- Figure 86 - Project MB4 Medical Biological Defense (ACD&P) - Botulinum
Vaccine - Program Funding [ $M ] - 2004- 2006
- Figure 87 - Project MB4 Medical Biological Defense (ACD&P) - Encephalitis
Vaccine - Program Funding [ $M ] - 2004- 2006
- Figure 88 - Project MB4 Medical Biological Defense (ACD&P) - Plague
Vaccine - Program Funding [ $M ] - 2004- 2006
- Figure 89 - Project MB5 Medical Biological Defense (SDD) - Botulinium
Vaccine - Program Funding [ $M ] - 2004- 2007
- Figure 90 - Project MB5 Medical Biological Defense (SDD) - Plague Vaccine
- Program Funding [ $M ] - 2004- 2007
11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 91 - DOD - Chemical Therapeutics HLS Pharmaceuticals R&D Budget
Forecast [ $M ] - 2006- 2010
- Figure 92 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Figure 93 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector - 2004, 2006 & 2010
- Figure 94 - Chemical Therapeutics - HLS Pharmaceuticals R&D Private
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 95 - Chemical Therapeutics - HLS Pharmaceuticals R&D Academia
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 96 - Chemical Therapeutics - HLS Pharmaceuticals R&D Government
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 97 - Project TC1 Medical Chemical Defense (Basic Research) -
Therapeutics - Program Funding [ $M ] - 2004- 2007
- Figure 98 - Nerve Agent Defense, Neuroprotection - Program Funding
[ $M ] - 2004- 2007
- Figure 99 - Vesicant Agent Defense, Vesicant Medical Countermeasures-
Program Funding [ $M ] - 2004- 2007
- Figure 100 - Chemical Warfare Agent Defense, Inhalation Therapeutics -
Program Funding [ $M ] - 2004- 2007
- Figure 101 - Project TC2 Medical Chemical Defense (Applied Research) -
Therapeutics - Program Funding [ $M ] - 2004- 2007
- Figure 102 - Project TC2 Medical Chemical Defense (Applied Research) -
Pretreatments - Program Funding [ $M ] - 2004- 2007
- Figure 103 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics -
Program Funding [ $M ] - 2004- 2007
- Figure 104 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics -
Anti-Convulsants - Program Funding [ $M ] - 2004- 2007
- Figure 105 - Project TC3 Medical Chemical Defense (ATD) - Neuroprotectors
- Program Funding [ $M ] - 2004- 2007
- Figure 106 - Project TC3 Medical Chemical Defense (ATD) - Vesicant Agent
Defense - Program Funding [ $M ] - 2004- 2007
- Figure 107 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics -
Skin and Wound Decontamination - Program Funding [ $M ] - 2004- 2007
- Figure 108 - Project TC3 Medical Chemical Defense (ATD) - Pretreatments -
Program Funding [ $M ] - 2004- 2007
- Figure 109 - Project MC4 Medical Chemical Defense (ACD&P) - Therapeutics
- Program Funding [ $M ] - 2004- 2007
- Figure 110 - Project MC4 Medical Chemical Defense (ACD&P) - Program
Funding [ $M ] - 2004- 2007
12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 111 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Budget Forecast by Major Departments [ $B ] - 2006- 2010
- Figure 112 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Budget Forecast by Major Departments Share - 2004, 2006 & 2010
- Figure 113 - NIH (DHHS) - Nuclear/Radiological Countermeasures HLS
Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 114 - DOD - Nuclear/Radiological Therapeutics HLS Pharmaceuticals
R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 115 - DOE - Nuclear/Radiological Therapeutics HLS Pharmaceuticals
R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 116 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Figure 117 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
- Figure 118 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 119 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 120 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 121 - Project TR2 Medical Radiological Defense - Program Funding
[ $M ] - 2004- 2007
- Figure 122 - Project TR3 Medical Radiological Defense - Program Funding
[ $M ] - 2004- 2011
- Figure 123 - Project MR4 Medical Radiological Defense - Program Funding
[ $M ] - 2004- 2011
- Figure 124 - Low Dose Radiation Research - Program Funding [ $M ] -
2004- 2006
13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 125 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by
Major Departments [ $M ] - 2006- 2010
- Figure 126 - Decontamination- HLS Pharmaceuticals R&D Budget Forecast by
Major Departments Share - 2004, 2006 & 2010
- Figure 127 - EPA - Decontamination HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- Figure 128 - DOD - Decontamination HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- Figure 129 - DHS - Decontamination HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- Figure 130 - DOE - Decontamination HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- Figure 131 - TSWG - Decontamination HLS Pharmaceuticals R&D Budget
Forecast - 2006- 2010
- Figure 132 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities
Forecast by Sector [ $M ] - 2006- 2010
- Figure 133 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities
Forecast Share by Sector - 2004, 2006 & 2010
- Figure 134 - Decontamination HLS Pharmaceuticals R&D Private Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 135 - Decontamination HLS Pharmaceuticals R&D Academia Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 136 - Decontamination HLS Pharmaceuticals R&D Government Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 137 - Immune Buildings - Program Funding [ $M ] - 2004-2007
- Figure 138 - External Protection Funding [ $M ] - 2004- 2007
- Figure 139 - Project CB1 - Decontamination - Program Funding [ $M ] -
2004 - 2007
- Figure 140 - Project CB2 - Decontamination - Program Funding [ $M ] -
2004 - 2007
- Figure 141 - Project CB3 Biological Defense (ATD) - Decontamination -
Program Funding [ $M ] - 2004 - 2007
- Figure 142 - Project DE4 Decontamination Systems (ACD&P) - Program
Funding [ $M ] 2004 - 2011
- Figure 143 - Project DE5 Decontamination Systems (SDD) - Program Funding
[ $M ] - 2004 - 2011
- Figure 144 - Industrial Operational Pollution Control Technology -
Program Funding [ $M ] - 2004 - 2007
- Figure 145 - Military Medical Environment - Program Funding [ $M ] -
2004 - 2007
- Figure 146 - Pollution Prevention - Program Funding [ $M ] - 2004 -
2007
- Figure 147 - Base Facility Environmental Quality - Program Funding
[ $M ] - 2004 - 2007
- Figure 148 - Environmental Remediation Science Research - Program Funding
[ $M ] - 2004- 2006
14. Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 149 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments
Budget
- Forecast [ $M ] - 2006- 2010
- Figure 150 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments
Budget Forecast Share - 2004, 2006 & 2010
- Figure 151 - DHHS - Diagnostics HLS Pharmaceuticals R&D Budget Forecast
[ $M ] - 2006- 2010
- Figure 152 - DOD - Diagnostics HLS Pharmaceuticals R&D Budget Forecast -
2006- 2010
- Figure 153 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Forecast by Sector [ $M ] - 2006- 2010
- Figure 154 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Forecast Share by Sector - 2004, 2006 & 2010
- Figure 155 - Diagnostics - HLS Pharmaceuticals R&D Private Sector Funding
Opportunities Forecast [ $M ] - 2006- 2010
- Figure 156 - Diagnostics - HLS Pharmaceuticals R&D Academia Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 157 - Diagnostics - HLS Pharmaceuticals R&D Government Sector
Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 158 - Insect Vector Control and Infectious Disease - Diagnostics -
Program Funding [ $M ] - 2004- 2007
- Figure 159 - Advanced Diagnostic - Program Funding [ $M ] - 2004-
2007
- Figure 160 - Project TB1 Medical Biological Defense (Basic Research) -
Diagnostics - Program Funding [ $M ] - 2004- 2007
- Figure 161 - Project TB2 Medical Biological Defense (Applied Research) -
Diagnostics - Program Funding [ $M ] - 2004- 2007
- Figure 162 - Project TB3 Medical Biological Defense (ATD) - Diagnostics -
Program Funding [ $M ] - 2004- 2007
- Figure 163 - Project MB5 Medical Biological Defense (SDD) - Diagnostics -
Program Funding [ $M ] - 2004- 2007
- Figure 164 - Project TC1 Medical Chemical Defense (Basic Research) -
Diagnostics - Program Funding [ $K ] - 2004- 2007
- Figure 165 - Project TC2 Medical Chemical Defense (Applied Research) -
Diagnostics - Program Funding [ $M ] - 2004- 2007
- Figure 166 - Project TC3 Medical Chemical Defense (ATD) - Diagnostics -
Program Funding [ $K ] - 2004- 2007
15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 167 - Food Protection Treatments HLS Pharmaceuticals R&D by Major
Departments Forecast - 2006- 2010
- Figure 168 - Food Protection Treatments HLS Pharmaceuticals R&D by Major
Departments Forecast Share - 2004, 2006 & 2010
- Figure 169 - DHHS - Food Protection Treatments HLS Pharmaceuticals R&D
Budget Forecast [ $M ] - 2006- 2010
- Figure 170 - USDA - Food Protection Treatments HLS Pharmaceuticals R&D
Budget Forecast [ $M ] - 2006- 2010
- Figure 171 - DHS - Food Protection Treatments HLS Pharmaceuticals R&D
Budget Forecast [ $M ] - 2006- 2010
- Figure 172 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Figure 173 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector - 2004, 2006 & 2010
- Figure 174 - Food Protection Treatments - HLS Pharmaceuticals R&D Private
Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 175 - Food Protection Treatments - HLS Pharmaceuticals R&D
Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 176 - Food Protection Treatments - HLS Pharmaceuticals R&D
Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
- Figure 177 - Livestock Protection - Program Funding [ $M ] - 2004-
2007
16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Figure 178 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006-
2010
- Figure 179 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 &
2010
- Figure 180 - DHHS - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 181 - DOD - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 182 - DHS - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 183 - NSF - Treatment for Emerging Biochemical Threats HLS
Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
- Figure 184 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] -
2006- 2010
- Figure 185 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004,
2006 & 2010
- Figure 186 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] -
2006- 2010
- Figure 187 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] -
2006- 2010
- Figure 188 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ]
- 2006- 2010
- Figure 189 - Biological Adaptation, Assembly & Manufacture - Program
Funding [ $M ] - 2004-2007
- Figure 190 - Nanostructure in Biology - Program Funding [ $M ] -
2004- 2007
- Figure 191 - Project CB1 Biological Defense (Basic Research) - Other -
Program Funding - 2004 - 2007
- Figure 192 - Project TB2 Medical Biological Defense (Applied Research) -
Emerging Threats - Program Funding [ $M ] - 2004 - 2007
- Figure 193 - Project TB3 Medical Biological Defense (ATD) - Emerging
Threats - Program Funding [ $M ] - 2004 - 2007
- Figure 194 - Project MB5 Medical Biological Defense (SDD) - Critical
Reagents Program (CRP) - Program Funding [ $M ] - 2004 - 2007
- Figure 195 - Project TC1 Medical Chemical Defense (Basic Research) -
Emerging Threats - Program Funding [ $M ] - 2004 - 2007
- Figure 196 - Non-Traditional Agents (NTAs) - Program Funding [ $M ] -
2004 - 2007
- Figure 197 - Project TC2 Medical Chemical Defense (Applied Research) -
Emerging Threats - Program Funding [ $M ] - 2004 - 2007
- Figure 198 - Project TC3 Medical Chemical Defense (ATD) - Emerging
Threats - Program Funding [ $M ] - 2004 - 2007
- Figure 199 - Project CB2 Chemical Defense (Applied Research) - Threat
Agent Sciences - Program Funding [ $M ] - 2004 - 2007
- Appendix A: The Homeland Security Federal R&D Infrastructure Figure 200 -
Homeland Security Federal R&D General Structure
List of Tables
1. Executive Summary
- Table 1 - HLS Pharmaceuticals R&D - Participating Agencies Funding for FY
2006 [ $M ]
- Table 2 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application
[ $M ] - 2006- 2010
- Table 3 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application
[ % ] - 2006- 2010
- Table 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector [ $M ] - 2006- 2010
- Table 5 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector Share [ % ] - 2006- 2010
2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006 - 2010
- Table 6 - Major S&T Initiatives in the National Strategy for Homeland
Security
- Table 7 - HLS Pharmaceuticals R&D - Participating Agencies and Programs
for FY 2006-2010
- Table 8 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency
[ $M ] - 2006- 2010
- Table 9 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency
Share [ % ] - 2006- 2010
- Table 10 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector [ $M ] - 2006- 2010
- Table 11 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by
Sector Share [ % ] - 2006- 2010
3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 12 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $M ] - 2006- 2010
- Table 13 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application
Share [ % ] - 2006- 2010
- Table 14 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 15 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 16 - DOD - Research, Development, Test & Evaluation by Agency
[ $B ] - 2004- 2006
- Table 17 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $M ] - 2006- 2010
- Table 18 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application
Share [ % ] - 2006- 2010
- Table 19 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency
[ $M ] - 2006- 2010
- Table 20 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency Share
[ % ] - 2006- 2010
- Table 21 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 22 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 23 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application
[ $M ] - 2006- 2010
- Table 24 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application
Share [ % ] - 2006- 2010
- Table 25 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 26 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 27 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast
[ $M ] - 2006- 2010
- Table 28 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast Share
[ % ] - 2006- 2010
- Table 29 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 30 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 31 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 32 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010
- Table 33 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 34 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 35 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast
by Major Departments [ $M ] - 2006- 2010
- Table 36 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast
by Major Departments [ % ] - 2006- 2010
- Table 37 - Biological Therapeutics HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Table 38 - Biological Therapeutics HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector [ % ] - 2006- 2010
10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 39 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major
Departments [ $M ] - 2006- 2010
- Table 40 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major
Departments [ % ] - 2006- 2010
- Table 41 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast
by Sector [ $M ] - 2006- 2010
- Table 42 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast
Share by Sector [ % ] - 2006- 2010
11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 43 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Table 44 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector [ % ] - 2006- 2010
12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 45 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Budget Forecast by Major Departments [ $M ] - 2006- 2010
- Table 46 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Budget Forecast by Major Departments [ % ] - 2006- 2010
- Table 47 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Table 48 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D
Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010
13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 49 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by
Major Departments [ $M ] - 2006- 2010
- Table 50 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by
Major Departments [ % ] - 2006- 2010
- Table 51 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities
Forecast by Sector [ $M ] - 2006- 2010
- Table 52 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities
Forecast Share by Sector [ % ] - 2006- 2010
14. Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 53 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments
Budget Forecast [ $M ] - 2006- 2010
- Table 54 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments
Budget Forecast Share [ % ] - 2006- 2010
- Table 55 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Forecast by Sector [ $M ] - 2006- 2010
- Table 56 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities
Forecast Share by Sector [ % ] - 2006- 2010
15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 57 - Food Protection Treatments HLS Pharmaceuticals R&D by Major
Departments Forecast [ $M ] - 2006- 2010
- Table 58 - Food Protection Treatments HLS Pharmaceuticals R&D by Major
Departments Forecast Share [ % ] - 2006- 2010
- Table 59 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Forecast by Sector [ $M ] - 2006- 2010
- Table 60 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding
Opportunities Forecast Share by Sector [ % ] - 2006- 2010
16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010
- Table 61 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006-
2010
- Table 62 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Budget Forecast by Major Departments Share [ % ] -
2006- 2010
- Table 63 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] -
2006- 2010
- Table 64 - Treatment for Emerging Biochemical Threats - HLS
Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] -
2006- 2010
- Appendix A: The Homeland Security Federal R&D Infrastructure
- Table 65 - Small Business Innovation Research Program - FY2006
- Table 66 - Small Business Technology Transfer Program - FY2006
|
 |
